PYC will have some form of listing in the USA by 2027.
The share register will be populated with leading life science institutions who will be able to compare apples with apples and pears with pears.
They will not be valuing PYC ground breaking, leading edge RnA science using proprietary CPP’s to delivery the drugs … by comparing with other Australian companies designing medical devices.
PYC will be elevated to a global stage well beyond Australian shores
The first 2 eye drugs can make the same level of profits as CSL currently (maybe much more if ADOA does also address macular degeneration)
The kidney cyst drug is only 12/18 months behind the eye drugs, and if trials successful … will make over 5x CSL current profits
comparing PYC valuations with CSL in the future is not pie in the sky to me … as PYC may be much bigger one day inside the next decade
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)